The Arg-403 to Gln mutation associated with familial hypertrophic cardiomyopathy does not quantitatively alter actin- or ATP-binding capacities in size-limited recombinant myosin heavy chain fragments.
Answers are grounded in this paper and cite their sources.
Challenges proposed direct binding defect for HCM mutation in truncated fragments; leaves open effects in full-length myosin or cellular models.
Our aim was to investigate the potential functional consequences of myosin heavy chain (MHC) mutations identified in patients with familial hypertrophic cardiomyopathy. We observed the presence of a mutated beta-MHC mRNA in a formalin-fixed paraffin-embedded myocardial tissue of a proband from family A, which Geisterfer-Lowrance et al. [Geisterfer-Lowrance, Kass, Tanigawa, Vosberg, McKenna, Seidman and Seidman (1990) Cell 62, 999-1006] identified as carrying the Arg-403 to Gln mutation. Recombinant DNA methods were then used to obtain size-limited, soluble and undenatured fragments of mutated myosin subfragment 1 focused around the 403 mutation. The present analysis indicated that the 403 mutation did not quantitatively alter the actin- or ATP-binding capacities of two 246-residue or 524-residue-long recombinant MHC fragments containing this mutation. The absence of any apparent impact of the 403 mutation in the recombinant MHC fragments on interactions between actin and ATP is discussed in relation to numerous biochemical and structural reports which demonstrate the crucial role of the central MHC segment, where the 403 mutation occurs, in myosin functions.
No takes yet. Share an insight, caveat, or question.
Eldin et al. (1995) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: